Drugs /

panobinostat

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
panobinostat
Trade Name(s):
Faridak and Farydak
NCI Definition [1]:
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.

Clinical Trials

View Clinical Trials for panobinostat

Panobinostat has been investigated in 12 clinical trials, of which 10 are open and 2 are closed. Of the trials investigating panobinostat, 1 is early phase 1 (1 open), 8 are phase 1 (7 open), and 3 are phase 2 (2 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for panobinostat clinical trials.

Multiple myeloma, diffuse intrinsic pontine glioma, and acute lymphoblastic leukemia are the most common diseases being investigated in panobinostat clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Panobinostat
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Panobinostat
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating panobinostat and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lbh589, Farydak, Faridak, (2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, (2e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, panobinostat (substance), 2-propenamide, n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2e)-, nvp-lbh589, panobinostat, hdac inhibitor lbh589, lbh 589, histone deacetylase inhibitor lbh589, panobinostat (product), panobinostat
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NCIT ID [1]:
C66948
SNOMED ID [1]:
C-78206

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.